Zealthy Review

The honest verdict: we list Zealthy as a warning, not a recommendation

Let's be direct from the first line, because this is the kind of decision where the details matter for your health and your wallet. Zealthy is the only provider on this site that we include specifically so you can see why we don't recommend it. It sells compounded semaglutide and tirzepatide through a fast, app-based telehealth funnel, and on the surface it looks like any other GLP-1 startup. Underneath, it carries two FDA warning letters, an active false-advertising lawsuit from Novo Nordisk, a federal DOJ/FTC enforcement action, and a founder whose last company settled with the FTC over similar conduct. If you read nothing else, read the trust section below before you click anything.

How Zealthy actually works, and the asynchronous trade-off

Zealthy runs an asynchronous model. You fill out an intake questionnaire, an independent licensed prescriber reviews it without a live video visit, and if approved your medication ships to your door. For some people that is genuinely convenient — no scheduling, no waiting room, no camera. The flip side is that there's no real-time conversation where you can ask questions, describe symptoms in your own words, or have a clinician push back. For a powerful injectable that affects appetite, blood sugar, and digestion, that lighter touch is a meaningful downside, not just a feature.

The company operates in 34 states, so coverage is reasonably broad but not nationwide. Worth knowing for context: the legal entity behind the brand is FitRX, LLC, which has reportedly been renamed to Gronk Inc. — a corporate reshuffle happening in the middle of active enforcement, which is rarely a reassuring sign.

The pricing model: a membership fee stacked on top of the medication

This is where the marketing and the math diverge. Zealthy doesn't charge one simple medication price. It charges for the medication AND layers a separate monthly membership fee on top of it. For compounded semaglutide that lands the all-in total in the upper-mid three figures per month; for tirzepatide it's higher still. Either way you're paying well above the category median of around $169 once the membership is included — and the membership is not a one-time cost, it recurs every month for as long as you stay.

• Two separate charges: the compounded drug itself, plus a recurring monthly membership fee billed on top of it.
• The membership is unavoidable — it's how the real monthly cost climbs well past what the headline drug price implies.
• Shipping and coaching are bundled into that membership, but you're paying a premium for them whether you use them or not.

Because the company does not publish a single clean standard rate — and because the federal complaint specifically alleges undisclosed subscription terms — you should treat any number you see in the funnel as something to confirm in writing before you hand over a card. Read exactly what recurs, how much, and how to stop it.

What you can actually get: compounded only, no brand names

Zealthy dispenses compounded semaglutide and compounded tirzepatide. It does not offer FDA-approved Ozempic, Wegovy, Zepbound, or Mounjaro. Compounded medications are made by a pharmacy rather than the original manufacturer, and they are not FDA-approved or independently tested for safety and effectiveness the way the brand products are. That distinction sits at the center of the legal trouble below: the FDA semaglutide shortage that once gave compounders legal room to operate ended in February 2025, and Zealthy is accused of continuing to market compounded semaglutide afterward.

The real reason to be cautious: FDA letters, lawsuits, and a familiar founder

This is the part that moves Zealthy to the bottom of our list. Every claim here is sourced to a primary government or court record, not rumor:

• FDA Warning Letter 717987 (Feb 2026) to FitRX, LLC for false or misleading marketing of compounded semaglutide and tirzepatide — including describing them as the 'active ingredient in Wegovy' and 'active ingredient in Zepbound' on products that are not FDA-approved.
• A second, earlier FDA enforcement action in a September 2025 cease-and-desist sweep targeting telehealth marketers of compounded GLP-1s after the shortage ended.
• An active Novo Nordisk lawsuit alleging trademark infringement and marketing compounded drugs as approved alternatives.
• An active DOJ/FTC enforcement action alleging undisclosed subscription terms, a locked or hard-to-use cancellation process, and unauthorized sharing of health data.
• The founder previously ran Cerebral, which settled with the FTC in 2024 over similar deceptive-practice allegations.

There are no accredited compounding-pharmacy partners listed in our record for Zealthy, and with an open FDA action on file we cannot vouch for its medical oversight the way we do for vetted providers. You can read how we weigh trust, accreditation, and enforcement history in our scoring methodology.

Who should skip Zealthy (almost everyone) and the narrow case for looking closer

Skip Zealthy if you want confidence that your provider is in good standing with regulators, transparent about recurring charges, and easy to cancel — which describes the vast majority of readers. The only reason we keep it visible at all is transparency: some people will search the brand, see slick ads, and deserve to find the documented enforcement record in one place before they sign up. If you're comparison-shopping, you can get compounded semaglutide or tirzepatide from providers that don't carry two FDA warning letters and an active federal case.

Bottom line

Zealthy is convenient and broadly available, but convenience is not the problem here — credibility is. Two FDA warning letters, a manufacturer lawsuit, a DOJ/FTC action over hidden subscriptions and data sharing, a mid-enforcement rebrand, and a founder with a prior FTC settlement add up to a pattern, not a coincidence. The added monthly membership also makes the true cost higher than the headline suggests. We list it for awareness and we do not recommend it. If you're set on compounded GLP-1 care, choose a provider with a clean regulatory record and pricing you can read in plain sight.

For a side-by-side, Maximus ($249.99/month) and MangoRx ($299/month) are the most comparable options to weigh against Zealthy.